▲ +218.87% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for F-star Therapeutics in the last 3 months. The average price target is $32.33, with a high forecast of $35.00 and a low forecast of $30.00. The average price target represents a 218.87% upside from the last price of $10.14.
The current consensus among 5 investment analysts is to buy stock in F-star Therapeutics.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.